Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP51A1 | Q16850 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6643536 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP51A1GAAAOC3CFTR | |
| SCHEMBL6319993 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP51A1GAAAOC3CFTR | |
| SCHEMBL10891176 | 0.80 | CYP51A1 (0.55) | SMN1; SMN2CYP51A1GAACFTRSLC6A2 | |
| SCHEMBL6284970 | 0.80 | AOC3 (0.68) | SMN1; SMN2AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6281184 | 0.79 | AOC3 (0.47) | CYP51A1AOC3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1579049 | 0.77 | LMNA (0.57) | SMN1; SMN2CYP51A1GAACFTRSLC6A2 | |
| SCHEMBL7629318 | 0.77 | SMN1; SMN2 (0.55) | SMN1; SMN2GAACFTRSLC6A2SLC6A4 | |
| SCHEMBL21009583 | 0.77 | LMNA (0.57) | SMN1; SMN2CYP51A1GAACFTRSLC6A2 | |
| SCHEMBL32346286 | 0.77 | LMNA (0.57) | SMN1; SMN2CYP51A1GAACFTRSLC6A2 | |
| SCHEMBL7952831 | 0.77 | LMNA (0.57) | SMN1; SMN2CYP51A1GAACFTRSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | claimed |
| US-6861438-B2 | Antiviral agents | PFIZER (US) | 2005-03-01 | — | — | US | disclosed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | SMN1; SMN2 947/4885CYP51A1 434/4885GAA 269/4885 |
| US-20040138449-A1 | Antiviral agents | IRF3, IFNAR1, EIF2AK2 | SMN1; SMN2 1122/4885CYP51A1 501/4885GAA 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.